In the U.S. the two populations at greatest risk of inappropriate, coercive, dangerous prescribing of highly toxic psychotropic drugs as chemical
restraints are the elderly and children.
"Corruption in any one of the critical decision points in the pharmaceutical system can be detrimental to a country’s ability to improve the health of its population." [World Banki]
“More than a year after the Food and Drug Administration announced it had strengthened its drug safety system, the agency still lacks a reliable system for keeping track of emerging problems, congressional investigators concluded in a report to be released today.” [Los Angeles Times, below]
Three reports illustrate the wide and deepening disconnect between medicine under the influence of pharmaceutical industry marketing goals and scientific evidence that contradicts current practice and public health policies:
APA "Diagnostic Statistical Manual" Task Force has been shown to have financial relationships with drug manufacturers.
Dr. Robert Spitzer, who has continued to play a central role in DSM revisions since 1980, claim he does not think a conflict of interest exists.
See list of APA Task Force on DSM-IV and DSM-IV Revised Text at: https://ahrp.stagenoises.ch/cms/content/view/145/27/
The undisclosed financial relationships between drug manufacturers and psychiatry’s leading "authorities" who determine what constitutes a “mental disorder” have been exposed.
The Tacoma Tribune reports that the head of the Center for Disease Control, Dr. Julie Gerberding, has reversed the agency’s bird flu policy, which viewed the threat from the worse-case scenario lens.
The APRIL 7, 2006 issue of SCIENCE Magazine contains one of the most important articles that tackles research fraud.
"Top Republicans — Senate Majority Leader Bill Frist, R-Tenn., and House Speaker Dennis Hastert, R-Ill– recently sold the future of our children to Big Pharma for a paltry $4 bucks a pop."
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
"Risks of anaphylaxis applies to all studies at PAREXEL, with drugs at every stage of development, and the staff are well trained in anticipation of this (unlikely) possibility.
